MwanzoMOLN • NASDAQ
add
Molecular Partners AG
Bei iliyotangulia
$ 4.32
Bei za siku
$ 4.32 - $ 4.70
Bei za mwaka
$ 3.32 - $ 12.70
Thamani ya kampuni katika soko
178.36M USD
Wastani wa hisa zilizouzwa
elfu 2.52
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (CHF) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 0.00 | -100.00% |
Matumizi ya uendeshaji wa biashara | 52.85M | 815.93% |
Mapato halisi | -11.23M | 43.22% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.30 | — |
EBITDA | -14.22M | 13.35% |
Asilimia ya kodi ya mapato | -0.02% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (CHF) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 149.44M | -20.04% |
Jumla ya mali | 158.53M | -20.08% |
Jumla ya dhima | 16.89M | -22.95% |
Jumla ya hisa | 141.64M | — |
hisa zilizosalia | 36.71M | — |
Uwiano wa bei na thamani | 1.12 | — |
Faida inayotokana na mali | -23.65% | — |
Faida inayotokana mtaji | -25.90% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (CHF) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -11.23M | 43.22% |
Pesa kutokana na shughuli | -13.20M | 17.47% |
Pesa kutokana na uwekezaji | -4.49M | -123.10% |
Pesa kutokana na ufadhili | 15.30M | 5,234.56% |
Mabadiliko halisi ya pesa taslimu | -1.88M | -72.29% |
Mtiririko huru wa pesa | -12.16M | -29.92% |
Kuhusu
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Ilianzishwa
2004
Tovuti
Wafanyakazi
162
